Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R. Schnell D, et al. Among authors: stopfer p. Cancer Chemother Pharmacol. 2014 Aug;74(2):267-75. doi: 10.1007/s00280-014-2484-y. Epub 2014 Jun 7. Cancer Chemother Pharmacol. 2014. PMID: 24906422 Free PMC article. Clinical Trial.
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Yap TA, et al. Among authors: stopfer p. J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679611 Clinical Trial.
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Doebele RC, Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, Stopfer P, Kaiser R, Camidge DR. Doebele RC, et al. Among authors: stopfer p. Ann Oncol. 2012 Aug;23(8):2094-2102. doi: 10.1093/annonc/mdr596. Epub 2012 Feb 16. Ann Oncol. 2012. PMID: 22345119 Free PMC article. Clinical Trial.
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Awada AH, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M, Schöffski P. Awada AH, et al. Among authors: stopfer p. Invest New Drugs. 2013 Jun;31(3):734-41. doi: 10.1007/s10637-012-9880-0. Epub 2012 Nov 17. Invest New Drugs. 2013. PMID: 23161334 Free PMC article. Clinical Trial.
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL. Marshall J, et al. Among authors: stopfer p. Invest New Drugs. 2013 Apr;31(2):399-408. doi: 10.1007/s10637-012-9890-y. Epub 2012 Nov 17. Invest New Drugs. 2013. PMID: 23161335 Free PMC article. Clinical Trial.
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J. Molife LR, et al. Among authors: stopfer p. Cancer Chemother Pharmacol. 2013 Dec;72(6):1213-22. doi: 10.1007/s00280-013-2286-7. Epub 2013 Oct 2. Cancer Chemother Pharmacol. 2013. PMID: 24085260 Clinical Trial.
45 results